Supplementary Material for: Polyradiculitis as a neurological complication associated with adagrasib: a case report

Adagrasib is an upcoming anti-cancer treatment for KRAS G12C-mutated non-small-cell lung carcinoma, colorectal cancer and potentially other solid tumors harboring this mutation. It is generally well-tolerated, and reports of neurological adverse events so far have been limited. We present to our best knowledge the first case of a 70-year-old woman who was admitted with polyradiculitis as a treatment-related complication of adagrasib. Symptoms resolved after treatment with prednisone and therapy interruption of adagrasib followed by a permanent dose reduction. After the dose reduction there was an ongoing effective tumor response at follow-up, and serum concentrations of adagrasib remained within the therapeutic index. Through this case report, we aim to bring attention to the possibility of this side effect, as we believe it is important to be aware of it for future patients undergoing treatment with adagrasib.